What does the evidence say about Saffron Anxiety Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Saffron Anxiety Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - However, due to some potentially significant adverse events associated with its medicinal use at higher doses or prolonged administration, clinical monitoring should be considered. [Hasheminasab FS (2026); evidence level 1] - Background Crocus sativus L., commonly known as saffron, is a widely used spice with a rich history of culinary and medicinal applications. [Hasheminasab FS (2026); evidence level 1] - This systematic review aims to compile human data from studies on monopreparations of C. [Hasheminasab FS (2026); evidence level 1] - This narrative review critically evaluates clinical evidence on commonly used herbal preparations, with particular emphasis on herb-drug interactions, adverse effects, and issues related to product adulteration. [Căuș MN (2026); evidence level 3] - However, clinically relevant risks were identified, including cytochrome P450-mediated drug interactions, excessive sedation, serotonin syndrome, and toxic effects associated with adulterated products, such as hepatotoxicity, cardiovascular events, and neurological disturbances. [Căuș MN (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.